A Gladstone Institutesled study finds blood protein destroys memory storage sites in the brain and may lead to new treatments. Led by Senior Investigator Katerina Akassoglou, PhD, Gladstone Institutes showed for the first time that a blood-clotting protein called fibrinogen is responsible for a series of molecular and cellular events that can destroy connections between neurons in the brain and result in cognitive decline. The Gladstone Institute’s team used state-of-the-art imaging technology to study both mouse brains and human brains from patients with Alzheimer’s disease. The investigative team also produced a three-dimensional volume imaging exhibiting blood-brain barrier leads occurring with Alzheimer’s disease. The study was recently published in the journal Neuron. The study was supported by the following:
- National Institute of Neurological Disorders and Stroke
- Swiss National Science Foundation
- Race to Erase MS
- American Heart Association
- Ray and Dagmar Dolby Family Fund
- H. Lundbeck A/S
- Conrad N. Hilton Foundation
Who is Gladstone Institutes?
With an annual budget of $80 million and over 450 employees, they are an independent and nonprofit biomedical research organization with a focus to better understand, prevent and treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer’s disease. They focus on basic and translational scientific methods. Another focus at Gladstone is building on the breakthrough development of induced pluripotent stem cell technology by one of its investigators, 2012 Noble Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration. They were founded in 1979 in affiliate with the University of California, San Francisco.
Lead Research/InvestigatorSource: Eurek Alert